Finanzen von Embecta Corp (EMBC)EMBCEmbecta Corp

Embecta Corp. (EMBC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Pen Needles, accounting for 65.3% of total sales, equivalent to $177.50M. Other significant revenue streams include Safety and Syringes. Understanding this composition is critical for investors evaluating how EMBC navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Embecta Corp. maintains a gross margin of 55.47%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 23.67%, while the net margin is 7.77%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively EMBC converts its operational activities into shareholder value.

In the context of the broader market, EMBC competes directly with industry leaders such as CV and OFIX. With a market capitalization of $378.49M, it holds a significant position in the sector. When comparing efficiency, EMBC's gross margin of 55.47% stands against CV's 51.36% and OFIX's 69.55%. Such benchmarking helps identify whether Embecta Corp. is trading at a premium or discount relative to its financial performance.

Embecta's gross margin has declined to 55.47% in Q3 2026, down from 65.99% in Q3 2025, reflecting worsening profitability. The company also reported a net income of $21.1 million in Q3 2026, down from $45.5 million in Q3 2025, indicating declining earnings.